BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime Sells 4,000 Shares

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 4,000 shares of the firm’s stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $92.55, for a total value of $370,200.00. Following the sale, the chief executive officer now owns 292,290 shares in the company, valued at approximately $27,051,439.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Wednesday, October 3rd, Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $99.36, for a total value of $149,040.00.
  • On Tuesday, September 4th, Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $98.16, for a total value of $147,240.00.

Shares of NASDAQ:BMRN opened at $97.96 on Monday. BioMarin Pharmaceutical Inc. has a 12-month low of $75.81 and a 12-month high of $106.74. The company has a quick ratio of 2.26, a current ratio of 2.87 and a debt-to-equity ratio of 0.28.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Thursday, October 25th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.15. BioMarin Pharmaceutical had a negative return on equity of 2.98% and a negative net margin of 8.35%. The firm had revenue of $391.71 million for the quarter, compared to analysts’ expectations of $369.43 million. As a group, analysts forecast that BioMarin Pharmaceutical Inc. will post -0.14 earnings per share for the current fiscal year.

A number of equities research analysts have weighed in on the company. BidaskClub downgraded BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday, August 1st. Wedbush restated an “outperform” rating and set a $120.00 price target (up previously from $115.00) on shares of BioMarin Pharmaceutical in a research report on Monday, August 6th. Barclays restated a “hold” rating and set a $98.00 price target (up previously from $95.00) on shares of BioMarin Pharmaceutical in a research report on Sunday, August 5th. Citigroup raised their price target on BioMarin Pharmaceutical from $108.00 to $120.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. Finally, Canaccord Genuity raised their price target on BioMarin Pharmaceutical from $105.00 to $113.00 and gave the company a “buy” rating in a research report on Tuesday, July 31st. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $117.00.

Several large investors have recently made changes to their positions in the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in shares of BioMarin Pharmaceutical by 2.2% during the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 24,493 shares of the biotechnology company’s stock valued at $2,307,000 after buying an additional 518 shares during the last quarter. Great West Life Assurance Co. Can grew its stake in shares of BioMarin Pharmaceutical by 0.6% in the second quarter. Great West Life Assurance Co. Can now owns 97,492 shares of the biotechnology company’s stock worth $9,186,000 after purchasing an additional 544 shares during the last quarter. Nissay Asset Management Corp Japan ADV grew its stake in shares of BioMarin Pharmaceutical by 4.8% in the second quarter. Nissay Asset Management Corp Japan ADV now owns 12,078 shares of the biotechnology company’s stock worth $1,138,000 after purchasing an additional 556 shares during the last quarter. Comerica Bank grew its stake in shares of BioMarin Pharmaceutical by 5.9% in the third quarter. Comerica Bank now owns 10,096 shares of the biotechnology company’s stock worth $1,012,000 after purchasing an additional 565 shares during the last quarter. Finally, US Bancorp DE grew its stake in shares of BioMarin Pharmaceutical by 5.6% in the second quarter. US Bancorp DE now owns 10,851 shares of the biotechnology company’s stock worth $1,021,000 after purchasing an additional 576 shares during the last quarter.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

Further Reading: Conference Calls

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply